23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Beam Therapeutics Inc. › 2025-2026

Beam Therapeutics Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Beam Therapeutics Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 288Asset managers, any item
  • 1,534Fund votes
  • June 3, 2026Meeting date

Results at a glance

Meeting of June 3, 2026: 5 items on Beam Therapeutics Inc.’s Form 8-K, filed June 8, 2026: 3 elected · 2 approved.

Dissent

Notable dissent: 1 director (10.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Beam Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Beam Therapeutics Inc.

These tallies are Beam Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Beam Therapeutics Inc. — official shareholder meeting results, meeting held June 3, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: John Evans 71,684,417864,042256,889 --13,419,659 99%Elected—
Elect Director: John Maraganore, Ph.D. 64,846,0807,701,591257,677 --13,419,659 89%Elected—
Elect Director: Christi Shaw 65,652,9596,893,102259,287 --13,419,659 90%Elected—
2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 85,754,272165,746304,989 ---- 99.8%Approved—
3. Compensation of the Company's named executive officers 71,546,749985,066273,533 --13,419,659 99%Approved—

Source: Beam Therapeutics Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.

How asset managers voted at the Beam Therapeutics Inc. 2025-2026 meeting

288 asset managers disclosed a vote on at least one Beam Therapeutics Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Christi Shaw

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 65,652,959AGAINST: 6,893,102
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: Christi Shaw

Beam Therapeutics Inc.’s own tally for this item (“Elect Director: Christi Shaw”): 65,652,959 for, 6,893,102 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 32,535,732 for, 906,587 against, 29,911 abstained.

FOR
FOR: 32,535,732AGAINST: 906,587ABSTAIN: 29,911
Largest asset managers voting on “Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of” at Beam Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust10,432,0260 00For
Vanguard8,899,21716 00For
Fidelity5,159,7350 00For
BlackRock2,218,3730 00For
State Street1,849,2012,166 00For
T. Rowe Price1,263,4140 00For
Charles Schwab808,3040 00For
ARK Venture Fund337,3100 00For
Equitable178,01569,200 00Mixed
AMERICAN BEACON FUNDS223,7570 00For
TIAA221,2070 00For
American Century0168,022 00Against
QUANTITATIVE MASTER SERIES LLC155,3670 00For
Brighthouse124,16417,701 00Mixed
First Trust0135,021 00Against
JPMorgan128,5860 00For
ProShares095,136 00Against
Dimensional092,406 00Against
Lincoln Financial71,83416,344 00Mixed
AIG/SunAmerica069,869 00Against
Russell Investments65,2830 00For
Transamerica60,0190 00For
Global X55,5000 00For
Janus Detroit Street Trust050,397 00Against
Northern Trust44,3620 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: John Evans

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 71,684,417AGAINST: 864,042
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Evans

Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Evans”): 71,684,417 for, 864,042 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 33,233,427 for, 208,890 against, 29,911 abstained.

FOR
FOR: 33,233,427AGAINST: 208,890ABSTAIN: 29,911
Largest asset managers voting on “Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of” at Beam Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust10,432,0260 00For
Vanguard8,890,9138,318 00For
Fidelity5,159,7350 00For
BlackRock2,218,3730 00For
State Street1,848,9512,416 00For
T. Rowe Price1,263,4140 00For
Charles Schwab808,3040 00For
ARK Venture Fund337,3100 00For
Equitable178,01569,200 00Mixed
AMERICAN BEACON FUNDS223,7570 00For
TIAA221,2070 00For
American Century168,0220 00For
QUANTITATIVE MASTER SERIES LLC155,3670 00For
Brighthouse141,8650 00For
First Trust135,0210 00For
JPMorgan128,5860 00For
ProShares95,1360 00For
Dimensional092,406 00Against
Lincoln Financial84,9943,184 00For
AIG/SunAmerica69,8690 00For
Russell Investments65,2830 00For
Transamerica60,0190 00For
Global X55,5000 00For
Janus Detroit Street Trust50,3970 00For
Northern Trust44,3620 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: John Maraganore, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 64,846,080AGAINST: 7,701,591
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Maraganore, Ph.D.

Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Maraganore, Ph.D.”): 64,846,080 for, 7,701,591 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 32,468,968 for, 973,349 against, 29,911 abstained.

FOR
FOR: 32,468,968AGAINST: 973,349ABSTAIN: 29,911
Largest asset managers voting on “Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of” at Beam Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust10,432,0260 00For
Vanguard8,890,8988,333 00For
Fidelity5,159,7350 00For
BlackRock2,218,3730 00For
State Street1,846,7854,582 00For
T. Rowe Price1,263,4140 00For
Charles Schwab808,3040 00For
ARK Venture Fund337,3100 00For
Equitable178,01569,200 00Mixed
AMERICAN BEACON FUNDS223,7570 00For
TIAA221,2070 00For
American Century0168,022 00Against
QUANTITATIVE MASTER SERIES LLC155,3670 00For
Brighthouse124,16417,701 00Mixed
First Trust0135,021 00Against
JPMorgan128,5860 00For
ProShares095,136 00Against
Dimensional092,406 00Against
Lincoln Financial71,83416,344 00Mixed
AIG/SunAmerica069,869 00Against
Russell Investments65,2830 00For
Transamerica60,0190 00For
Global X55,5000 00For
Janus Detroit Street Trust050,397 00Against
Northern Trust044,362 00Against

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 71,546,749AGAINST: 985,066
Details: description as filed, official tally, votes by 288 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.

Beam Therapeutics Inc.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 71,546,749 for, 985,066 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 66 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at Beam Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust10,432,0260 00For
Vanguard8,899,2301 00For
Fidelity5,159,7350 00For
BlackRock2,218,3730 00For
State Street1,850,597770 00For
T. Rowe Price1,263,4140 00For
Charles Schwab808,3040 00For
ARK Venture Fund337,3100 00For
Equitable247,2150 00For
AMERICAN BEACON FUNDS223,7570 00For
TIAA221,2070 00For
American Century0168,022 00Against
QUANTITATIVE MASTER SERIES LLC155,3670 00For
Brighthouse141,8650 00For
First Trust135,0210 00For
JPMorgan128,5860 00For
ProShares95,1360 00For
Dimensional92,4060 00For
Lincoln Financial88,1780 00For
AIG/SunAmerica69,8690 00For
Russell Investments65,2830 00For
Transamerica60,0190 00For
Global X55,5000 00For
Janus Detroit Street Trust50,3970 00For
Northern Trust44,3620 00For

Fund voting reports, all 66 managers: 33,265,328 for, 176,781 against, 29,911 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 237 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at Beam Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity8,394,9410 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.6,441,2670 00For
ARCH Venture Management, LLC4,540,1320 00For
Amova Asset Management Co., Ltd.3,822,3890 00For
State Street3,057,52520,386 00For
BlackRock2,108,66211,751 00For
T. Rowe Price1,825,9630 00For
Kynam Capital Management, LP00 01,570,747Withhold
GEODE CAPITAL MANAGEMENT, LLC1,551,4830 00For
Redmile Group, LLC1,164,2590 00For
Impresa Management LLC1,139,4430 00For
Deep Track Capital, LP1,000,0000 00For
Vanguard832,8340 00For
Charles Schwab808,9400 00For
ARK Investment Management LLC628,9030 00For
RTW INVESTMENTS, LP570,3940 00For
Contrarius Group Holdings Ltd526,8650 00For
Northern Trust470,9899,721 00For
ADAR1 Capital Management, LLC393,1420 00For
Two Sigma350,3180 00For
GV Management Company, L.L.C.321,6030 00For
PICTET ASSET MANAGEMENT SA282,5840 00For
Goldman Sachs263,3970 00For
UBS0232,844 00Against
Nuveen232,6200 00For

Institutional-manager reports, all 237 managers: 43,536,247 for, 607,998 against, 1,570,747 withheld, 3,694 abstained, 252 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 85,754,272AGAINST: 165,746
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Beam Therapeutics Inc.’s own tally for this item (“2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026”): 85,754,272 for, 165,746 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 was ratified, based on the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 33,441,548 for, 770 against, 29,911 abstained.

FOR
FOR: 33,441,548AGAINST: 770ABSTAIN: 29,911
Largest asset managers voting on “RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR F” at Beam Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust10,432,0260 00For
Vanguard8,899,2320 00For
Fidelity5,159,7350 00For
BlackRock2,218,3730 00For
State Street1,850,597770 00For
T. Rowe Price1,263,4140 00For
Charles Schwab808,3040 00For
ARK Venture Fund337,3100 00For
Equitable247,2150 00For
AMERICAN BEACON FUNDS223,7570 00For
TIAA221,2070 00For
American Century168,0220 00For
QUANTITATIVE MASTER SERIES LLC155,3670 00For
Brighthouse141,8650 00For
First Trust135,0210 00For
JPMorgan128,5860 00For
ProShares95,1360 00For
Dimensional92,4060 00For
Lincoln Financial88,1780 00For
AIG/SunAmerica69,8690 00For
Russell Investments65,2830 00For
Transamerica60,0190 00For
Global X55,5000 00For
Janus Detroit Street Trust50,3970 00For
Northern Trust44,3620 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Largest Beam Therapeutics Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 102,741,848 shares outstanding at the time of that meeting.

Fund voting reports: top Beam Therapeutics Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1ARK ETF Trust 10.15%
2Vanguard 8.66%
3Fidelity 5.02%
4BlackRock 2.16%
5State Street 1.80%
6T. Rowe Price 1.23%
7Charles Schwab 0.79%
8ARK Venture Fund 0.33%
9Equitable 0.24%
10AMERICAN BEACON FUNDS 0.22%
Institutional-manager reports: top Beam Therapeutics Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 8.17%
2FARALLON CAPITAL MANAGEMENT, L.L.C. 6.27%
3ARCH Venture Management, LLC 4.42%
4Amova Asset Management Co., Ltd. 3.72%
5State Street 3.00%
6BlackRock 2.06%
7T. Rowe Price 1.78%
8Kynam Capital Management, LP 1.53%
9GEODE CAPITAL MANAGEMENT, LLC 1.51%
10Redmile Group, LLC 1.13%

Reported Beam Therapeutics Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Beam Therapeutics Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR LLC and affiliates12,750,369 12.41%Proxy statement (DEF 14A), table as of December 31, 2025
FMR (Fidelity)12,452,199 12.12%Form 13F, quarter ended March 31, 2026
Farallon Capital Management, L.L.C.10,282,210 10.01%Schedule 13G, filed August 13, 2026
ARK Investment Management LLC10,234,862 9.96%Schedule 13G, filed August 14, 2026
Farallon Capital Partners LP and affiliates10,141,856 9.87%Proxy statement (DEF 14A), table as of December 31, 2025
Vanguard Group9,193,474 8.95%Form 13F, quarter ended March 31, 2026
BlackRock8,487,569 8.26%Form 13F, quarter ended March 31, 2026
STATE STREET CORPORATION5,228,529 5.09%Schedule 13G, filed February 9, 2026
T. Rowe Price2,713,230 2.64%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors2,154,575 2.10%Form 13F, quarter ended March 31, 2026

Percentages above are of 102,741,848 shares outstanding, as reported by Beam Therapeutics Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Beam Therapeutics Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 288 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,534 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — Beam Therapeutics Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Beam Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Beam Therapeutics Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Beam Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Beam Therapeutics (BEAM) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/beam-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.